A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Trial Parameters
Brief Summary
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. The participant provides written informed consent 2. ≥ 18 years of age on day of signing informed consent. 3. Participant with histologically or cytologically confirmed diagnosis of advanced unresectable and/or metastatic solid tumors 4. A male participant must agree to use contraception and refrain from sperm donation or expecting to father a child 5. A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential 6. Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology 7. Able to provide tumor tissue sample. 8. Willing to undergo fresh tumor biopsy at Screening and On-treatment if archival tissue not available 9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 10. Life expectancy greater than or equal to 12 weeks as judged by the Investigator. 11. Have adequate organ function Exclusion Criteria: 1. A WOCBP who has a positive seru